Surviving Grade 4 ICANS: A Case Report and Discussion of Emerging Management Strategies

Area of Science:

• Immunotherapy
• Neuroscience
• Hematology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is a growing treatment for various conditions.
• Severe immune effector cell-associated neurotoxicity syndrome (ICANS) is a rare but life-threatening complication.
• Effective management strategies for severe ICANS are critical due to the increasing use of CAR T-cell therapies.

Observation:

• A young adult with relapsed acute lymphoblastic leukemia developed grade 4 ICANS.
• The patient presented with severe cerebral edema unresponsive to initial treatments.
• This case highlights the challenges in managing severe CAR T-cell-related neurotoxicity.

Findings:

• A treatment strategy involving targeted immunotherapy and intracranial pressure monitoring was implemented.
• The patient experienced a meaningful neurologic recovery and remains in remission.
• This approach demonstrates a potential pathway for managing refractory ICANS.

Implications:

• Neurologists must be prepared to manage severe ICANS, a critical aspect of CAR T-cell therapy.
• Early recognition and proactive management are key to improving outcomes in neurotoxicity.
• This case underscores the need for specialized protocols for managing severe CAR T-cell-induced neurotoxicity.